Jordi Tortosa-Carreres

Dr. Jordi Tortosa-Carreres

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 June 2024 in Multiple Sclerosis and Related Disorders
Verified
Journal Article
Closed access
JTJordi Tortosa-Carreres
Jordi Tortosa-Carreres
LCLaura Cubas-Núñez
Laura Cubas-Núñez
AQAna Quiroga-Varela
Ana Quiroga-Varela
JCJessica Castillo-Villalba
Jessica Castillo-Villalba
LRLluís Ramió-Torrenta
Lluís Ramió-Torrenta
FPFrancisco Carlos Pérez-Miralles
Francisco Carlos Pérez-Miralles

9 September 2023 in Multiple Sclerosis and Related Disorders
Verified
Journal Article
Closed access
JTJordi Tortosa-Carreres
Jordi Tortosa-Carreres
AQAnna Quiroga-Varela
Anna Quiroga-Varela
JCJessica Castillo-Villalba
Jessica Castillo-Villalba
MPMónica Piqueras-Rodríguez
Mónica Piqueras-Rodríguez
LRLluís Ramió-Torrenta
Lluís Ramió-Torrenta
FPFrancisco Carlos Pérez-Miralles
Francisco Carlos Pérez-Miralles

23 September 2024 in Neurological Sciences
Verified
Journal Article
Closed access
PDF file
JTJordi Tortosa-Carreres
Jordi Tortosa-Carreres
LCLaura Cubas-Núñez
Laura Cubas-Núñez
MSMaría T. Sanz
María T. Sanz
JCJessica Castillo-Villalba
Jessica Castillo-Villalba
RGRaquel Gasqué-Rubio
Raquel Gasqué-Rubio
FMFrancisco Carlos Pérez Miralles
Francisco Carlos Pérez Miralles

20 October 2025 in Frontiers in Neurology
Verified
Journal Article
Open access
PDF file
JTJordi Tortosa-Carreres
Jordi Tortosa-Carreres
LCLaura Cubas-Núñez
Laura Cubas-Núñez
JCJéssica Castillo-Villalba
Jéssica Castillo-Villalba
LFLorena Forés-Toribio
Lorena Forés-Toribio
RGRaquel Gasque-Rubio
Raquel Gasque-Rubio
BCBonaventura Casanova
Bonaventura Casanova
Introduction: Serum glial fibrillary acidic protein (sGFAP) is a promising biomarker, but its quantification mainly relies on SIMOA, a technology not widely available in clinical practice.Objectives: To evaluate the analytical performance of two high-throughput automated platforms—Alinity® i (Abbott) and Lumipulse® G1200 (Fujirebio)—for sGFAP quantification.Methods: A retrospective longitudinal study included 107 serum samples from 23 MS patients. sGFAP was measured with SIMOA SR-X®, Lumipulse® G1200, and Alinity® i. Data were log-transformed. Agreement was assessed using Pearson correlations, Passing–Bablok regression, Bland–Altman analysis, and Δlog correlations between visits. Longitudinal differences across platforms were tested with a linear mixed-effects model (platform as fixed effect, SIMOA as reference). Moreover, ΔSIMOA was modeled against ΔLumipulse and ΔAlinity, adjusting for ΔEDSS, phenotype, relapses and new MRI lesions.Results: Passing–Bablok regression yielded slopes of 0.85 (SIMOA–Lumipulse), 0.81 (SIMOA–Alinity), and 0.95 (Lumipulse–Alinity), with intercepts of −0.32, −0.35, and −0.05. Mean log-biases were −0.622, −0.733, and 0.109. Correlations between log-means and log-differences were r = 0.26 (p = 0.006), 0.44 (p < 0.0001), and 0.15 (p = 0.13). The mixed-effects model showed no significant Δlog differences relative to SIMOA (p > 0.1). When modeling ΔSIMOA, ΔLumipulse was a significant predictor (β = 0.51; p = 0.002), whereas ΔAlinity showed only a trend (β = 0.31; p = 0.051). No clinical covariates were significantly associated.Conclusion: Automated platforms, particularly Lumipulse, showed strong concordance with SIMOA supporting the role in analytical monitoring.

24 December 2023 in Diagnostic Microbiology and Infectious Disease
Verified
Journal Article
Closed access
JTJordi Tortosa-Carreres
Jordi Tortosa-Carreres
CLCarmen Lloret-Sos
Carmen Lloret-Sos
JSJose Miguel Sahuquillo-Arce
Jose Miguel Sahuquillo-Arce
PSPedro Suárez-Urquiza
Pedro Suárez-Urquiza
JPJosep Prat-Fornells
Josep Prat-Fornells
JHJose Luis Lopez- Hontangas
Jose Luis Lopez- Hontangas

29 September 2025 in Clinical Chemistry and Laboratory Medicine (CCLM)
Verified
Journal Article
Closed access
JTJordi Tortosa-Carreres
Jordi Tortosa-Carreres
AVAna Vañó-Bellver
Ana Vañó-Bellver
AMAndreu Martínez-Cerezuela
Andreu Martínez-Cerezuela
ÓFÓscar Fuster-Lluch
Óscar Fuster-Lluch
LGLucía García-Ruiz
Lucía García-Ruiz
BLBegoña Laiz-Marro
Begoña Laiz-Marro
Objectives: To develop and validate a machine-learning model based on routinely available biochemical and hematological parameters for detecting wrong blood in tube (WBIT) errors in hospitalized patients. Methods: A retrospective multicenter study including one internal cohort (IC) and two external validation cohorts (EVC, EVC2). The IC was balanced (50 % correct, 50 % WBIT; 25 % real, 25 % simulated), while EVC (n=800) and EVC2 (n=460) represented more realistic scenarios (95 % correct, 5 % WBIT; equally distributed between real and simulated). Parameters present in ≥ 95 % of requests were selected, and their normalized variation from the immediately preceding result was calculated. The IC was divided into a training set (IC-TS, n=324) and an internal validation set (IC-VS, n=108). Feature selection was refined with Elastic Net before training an XGBoost model. Performance was assessed in IC-VS, EVC, and EVC2. For benchmarking, the model’s discriminative ability was also compared with a multivariate Mahalanobis-based approach and with univariate delta checks within IC-TS/IC-VS. Results: Sixteen of 25 candidate variables were retained. The model achieved ROC-AUC values of 0.98–0.99 and PR-AUC values of 0.93–0.99 across all validation cohorts. Recalibration improved positive predictive value and net benefit by reducing false positives, with a slight decrease in sensitivity, although all values remained ≥90 %. Specificities ranged from 98 to 99 %. The model consistently outperformed both the multivariate Mahalanobis approach and univariate delta checks within the internal cohort. Conclusions: This machine-learning model, leveraging widely available routine laboratory parameters, shows strong potential for integration into clinical workflows, enhancing WBIT detection and improving patient safety.